Lisata Therapeutics Inc 8NE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 8NE is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €3.24
- Day Range
- €3.30–3.30
- 52-Week Range
- €1.84–5.00
- Bid/Ask
- €3.28 / €3.44
- Market Cap
- €27.41 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.lisata.com
Valuation
Metric
|
8NE
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
8NE
|
---|---|
Quick Ratio | 8.13 |
Current Ratio | 8.92 |
Interest Coverage | — |
Quick Ratio
8NE
Profitability
Metric
|
8NE
|
---|---|
Return on Assets (Normalized) | −31.90% |
Return on Equity (Normalized) | −35.13% |
Return on Invested Capital (Normalized) | −35.16% |
Return on Assets
8NE
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Vertex Pharmaceuticals Inc
VRTX
| Fbbdhwhn | Vyfzjyk | $124.1 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Lmbpqrsck | Lntgtzn | $114.2 Bil | |||
Moderna Inc
MRNA
| Tcgrgfvb | Clppm | $53.7 Bil | |||
argenx SE ADR
ARGX
| Crgjmmyqg | Mnxm | $23.0 Bil | |||
BioNTech SE ADR
BNTX
| Zpfskrlzz | Ktd | $22.2 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Gkjfvtth | Nbltrd | $20.3 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Rdqnkgky | Jbmtf | $15.9 Bil | |||
United Therapeutics Corp
UTHR
| Hwjfwbng | Tnkq | $12.8 Bil | |||
Incyte Corp
INCY
| Zrzyvdpys | Rcjqfz | $12.2 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Rnfvbpcs | Shqzhz | $12.2 Bil |